Ligand Pharmaceuticals Inc
NASDAQ:LGND

Watchlist Manager
Ligand Pharmaceuticals Inc Logo
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Watchlist
Price: 115.43 USD -5.45%
Market Cap: 2.1B USD
Have any thoughts about
Ligand Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one LGND stock under the Base Case scenario is 51.48 USD. Compared to the current market price of 115.43 USD, Ligand Pharmaceuticals Inc is Overvalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LGND Relative Value
Base Case
51.48 USD
Overvaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
37
Median 3Y
6.7
Median 5Y
7.2
Industry
8.1
Forward
12.8
vs History
11
vs Industry
8
Median 3Y
26.5
Median 5Y
21.3
Industry
23
Forward
20.6
vs History
4
vs Industry
3
Median 3Y
11
Median 5Y
18.9
Industry
23.4
vs History
vs Industry
8
Median 3Y
-10.8
Median 5Y
-9
Industry
27.3
vs History
0
vs Industry
40
Median 3Y
1.8
Median 5Y
1.6
Industry
2.6
vs History
0
vs Industry
35
Median 3Y
5.9
Median 5Y
5.8
Industry
8.1
Forward
11.4
vs History
0
vs Industry
31
Median 3Y
7.6
Median 5Y
7.3
Industry
9.6
vs History
15
vs Industry
3
Median 3Y
13
Median 5Y
18.2
Industry
4.3
Forward
23.5
vs History
4
vs Industry
0
Median 3Y
28.2
Median 5Y
27.9
Industry
3.8
Forward
175.9
vs History
4
vs Industry
3
Median 3Y
9.6
Median 5Y
16.6
Industry
6
vs History
vs Industry
8
Median 3Y
8.7
Median 5Y
9.5
Industry
3.8
vs History
0
vs Industry
43
Median 3Y
1.7
Median 5Y
1.7
Industry
4.8

Multiples Across Competitors

LGND Competitors Multiples
Ligand Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
2.1B USD 15.5 49.2 42.2 231.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average P/E: 184.7
49.2
163%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average EV/EBITDA: 21.3
42.2
289%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average EV/EBIT: 52.9
231.4
1 041%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top